Mlcáková A, Babusíková O
Cancer Research Institute, Slovak Academy of Sciences, 833 91 Bratislava, Slovak Republic.
Neoplasma. 2003;50(6):416-21.
Leukemic cells can be distinguished from normal hematopoietic cells on the basis of chromosomal or molecular abnormalities, antigen receptor gene rearrangements and immunophenotype. Set of 3-, 4-combination of monoclonal antibodies was used for exact definition of immunophenotypic characteristics of B-cells populations from healthy donors and aberrant, asynchronous, over/under-expressed phenotypes and detection changes in intensity expression of markers that characterized pathological leukemic B-cells at diagnosis. These differences in normal and abnormal cell patterns were very important and could be utilized for analysis of minimal residual disease. On the basis of these findings we were able to clearly distinguish residual leukemic cells from hematogones (healthy B-lymphocyte precursors) too. We also verified that in some cases the CD58 marker is overexpressed on CD10+, CD34+ blast cells at diagnosis and can be feasible used for detection of minimal residual disease (MRD).
白血病细胞可根据染色体或分子异常、抗原受体基因重排和免疫表型与正常造血细胞区分开来。使用一组3种、4种单克隆抗体组合来精确界定健康供体B细胞群体的免疫表型特征以及异常、不同步、过表达/低表达的表型，并检测诊断时表征病理性白血病B细胞的标志物强度表达变化。正常和异常细胞模式的这些差异非常重要，可用于分析微小残留病。基于这些发现，我们也能够清楚地区分残留白血病细胞和造血细胞（健康B淋巴细胞前体）。我们还证实，在某些情况下，CD58标志物在诊断时于CD10+、CD34+母细胞上过度表达，可用于检测微小残留病（MRD）。
